Paid Clinical Trials Alabama
Discover 1,089 paid clinical trials in Alabama. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
ImmunotherapyImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sponsor:
Sabine Mueller, MD, PhD
Location:
Code:
NCT04323046
Conditions
Glioblastoma
Malignant Glioma
Recurrent Glioblastoma
Recurrent Malignant Glioma
Recurrent Grade III Glioma
Eligibility Criteria
Sex: All
Age: 6 - 25
Healthy Volunteers: Not accepted
Interventions
Nivolumab
Quality-of-Life Assessment
Questionnaire Administration
PF-08046054A Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
Efgartigimod PH20A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
Sponsor:
argenx
Location:
Code:
NCT06503731
Conditions
Antibody-mediated Rejection
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Efgartigimod PH20 SC - prefilled syringe
Placebo PH20 SC - prefilled syringe
AB-101 & B-Cell Depleting mAbAB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Sponsor:
Artiva Biotherapeutics, Inc.
Location:
Code:
NCT06265220
Conditions
Lupus Nephritis - WHO Class III
Lupus Nephritis - WHO Class IV
Refractory Systemic Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
AB-101
Cyclophosphamide
Fludarabine
Rituximab
Obinutuzumab
Nivolumab & TovorafenibNivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Sponsor:
Sabine Mueller, MD, PhD
Location:
Code:
NCT05465174
Conditions
Craniopharyngioma, Child
Craniopharyngioma
Recurrent Craniopharyngioma
Eligibility Criteria
Sex: All
Age: 1 - 39
Healthy Volunteers: Not accepted
Interventions
Nivolumab
Tovorafenib
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
177Lu-DOTATATE vs. EverolimusComparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05773274
Conditions
Metastatic Midgut Neuroendocrine Tumor
Metastatic Midgut Neuroendocrine Tumor G1
Metastatic Midgut Neuroendocrine Tumor G2
Unresectable Midgut Neuroendocrine Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Everolimus
Lutetium Lu 177 Dotatate
Quality-of-Life Assessment
Harmony TPVHarmony TPV Post-Approval Study
Sponsor:
Medtronic Cardiovascular
Location:
Code:
NCT05077774
Conditions
Congenital Heart Disease
Tetrology of Fallot
RVOT Anomaly
Pulmonary Regurgitation
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Harmony TPV System
LitifilimabA 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)
Sponsor:
Biogen
Location:
Code:
NCT05531565
Conditions
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Litifilimab
Placebo
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression